Io­n­is sells par­tial stake in roy­al­ties from Spin­raza and No­var­tis car­dio drug to Roy­al­ty Phar­ma for $500M up­front

Io­n­is is sell­ing per­cent­ages of its roy­al­ties in Bio­gen’s Spin­raza and po­ten­tial roy­al­ties in No­var­tis’ pelacarsen to Roy­al­ty Phar­ma in ex­change for $500 mil­lion cash …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER